StreetInsider.com News Articles

Form 424B3 MindMaze Therapeutics

Thu, 16 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260416/26325003.html

Form 424B3 MindMaze Therapeutics

Thu, 16 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260416/26325003.html

Form 424B3 MindMaze Therapeutics

Thu, 16 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260416/26325003.html

Relief Therapeutics Shareholders Approve Business Combination with NeuroX

Fri, 14 Nov 2025 12:40:00 -0400

Shareholders approve all EGM proposals related to the combination with NeuroX
Business combination expected to close in December 2025
Relief to be renamed MindMaze Therapeutics Holding SA upon closing
New board and executive committee members announced
Companies to host joint press conference on November 25, 2025

GENEVA, SWITZERLAND / ACCESS Newswire / November 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced that shareholders approved by a large

Relief Therapeutics Shareholders Approve Business Combination with NeuroX

Fri, 14 Nov 2025 12:40:00 -0400

Shareholders approve all EGM proposals related to the combination with NeuroX
Business combination expected to close in December 2025
Relief to be renamed MindMaze Therapeutics Holding SA upon closing
New board and executive committee members announced
Companies to host joint press conference on November 25, 2025

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

Wed, 29 Oct 2025 02:20:00 -0400

RLF-OD032 demonstrated bioequivalence to KUVAN^® Powder
Study results support planned 505(b)(2) NDA submission in early 2026

GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief's innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of phenylketonuria (PKU).

The pivotal

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

Wed, 29 Oct 2025 02:20:00 -0400

RLF-OD032 demonstrated bioequivalence to KUVAN^® Powder
Study results support planned 505(b)(2) NDA submission in early 2026

The pivotal

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

Wed, 29 Oct 2025 02:20:00 -0400

RLF-OD032 demonstrated bioequivalence to KUVAN^® Powder
Study results support planned 505(b)(2) NDA submission in early 2026

The pivotal

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

Wed, 29 Oct 2025 02:20:00 -0400

RLF-OD032 demonstrated bioequivalence to KUVAN^® Powder
Study results support planned 505(b)(2) NDA submission in early 2026

The pivotal

Relief Therapeutics Publishes 2025 Half-Year Report

Thu, 14 Aug 2025 01:20:00 -0400

GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update.

"Relief continued to make steady progress across our pipeline and corporate initiatives," said Dr. Raghuram Selvaraju, chairman of the board of directors. "We advanced RLF‑TD011, our lead wound care candidate, with

Relief Therapeutics Publishes 2025 Half-Year Report

Thu, 14 Aug 2025 01:20:00 -0400

Relief Therapeutics Publishes 2025 Half-Year Report

Thu, 14 Aug 2025 01:20:00 -0400

Relief Therapeutics Publishes 2025 Half-Year Report

Thu, 14 Aug 2025 01:20:00 -0400

Relief Therapeutics Advances Publication of 2025 Half-Year Report

Mon, 11 Aug 2025 01:20:00 -0400

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.

The change in publication date is due to the

Relief Therapeutics Advances Publication of 2025 Half-Year Report

Mon, 11 Aug 2025 01:20:00 -0400

The change in publication date is due to the

Relief Therapeutics Advances Publication of 2025 Half-Year Report

Mon, 11 Aug 2025 01:20:00 -0400

The change in publication date is due to the

Relief Therapeutics Advances Publication of 2025 Half-Year Report

Mon, 11 Aug 2025 01:20:00 -0400

The change in publication date is due to the

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

Tue, 29 Jul 2025 01:20:00 -0400

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders
Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company
Binding term sheet signed; transaction subject to customary conditions and approvals
Closing expected in Q4 2025

GENEVA, SWITZERLAND / ACCESS Newswire / July 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ("Relief" or the "Company"), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

Tue, 29 Jul 2025 01:20:00 -0400

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders
Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company
Binding term sheet signed; transaction subject to customary conditions and approvals
Closing expected in Q4 2025

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

Tue, 29 Jul 2025 01:20:00 -0400

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders
Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company
Binding term sheet signed; transaction subject to customary conditions and approvals
Closing expected in Q4 2025

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

Tue, 29 Jul 2025 01:20:00 -0400

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders
Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company
Binding term sheet signed; transaction subject to customary conditions and approvals
Closing expected in Q4 2025

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

Fri, 20 Jun 2025 01:20:00 -0400

GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial request for Qualified Infectious Disease Product (QIDP) designation for RLF-TD011 for the treatment of epidermolysis bullosa (EB) was not granted by the U.S. Food and Drug Administration (FDA). The FDA determined that the investigational therapy does not currently meet the criteria for QIDP

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

Fri, 20 Jun 2025 01:20:00 -0400

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

Fri, 20 Jun 2025 01:20:00 -0400

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

Fri, 20 Jun 2025 01:20:00 -0400